Innovent Announces Oral Presentations At ESMO Plenary And ESMO GI Congress On Clinical Data Of IBI363 (PD-1/IL-2) And IBI343 (CLDN18.2 ADC)

SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharma

Related Keywords

Sydney ,New South Wales ,Australia ,Munich ,Bayern ,Germany ,China ,Rhui Zhou ,Guangdong ,Zhejiang ,Suzhou ,Jiangsu ,Innovent Biologics ,Eli Lilly ,Xueli Bai ,Adimab Incyte ,Jia Jenny Liu ,Md Anderson Cancer Center ,Gastrointestinal Cancers Congress ,Linkedin ,Zhejiang University School Of Medicine ,Innovent Biologics Inc ,Cancers Congress ,Zhejiang University School ,Senior Vice President ,